Insider Profile · SEC Form 4 Activity · Trailing 90 Days
Stengone Carmine N.
Over the trailing 90 days, Stengone Carmine N. (Director at Contineum Therapeutics, Inc.) traded $213K of stock (net selling $187K) across 2 companies, per 9 SEC Form 4 transactions.
- Role
- Director
- Window
- Trailing 90 days · 9 transactions · CIK 1861519
- Net activity
- −$187K ($13K bought · $200K sold)
By Company (Trailing 90 Days)
Transactions (9)
| Date | Symbol | Type | Shares | Value | Description |
|---|---|---|---|---|---|
| 2026-07-08 | CTNM | Sell | 2.5K | $0 | Exercise or conversion of derivative security |
| 2026-07-08 | CTNM | Buy | 2.5K | $3K | Exercise or conversion of derivative security |
| 2026-07-08 | CTNM | Sell | 2.5K | $40K | Open market or private sale |
| 2026-06-30 | CTNM | Sell | 7.5K | $0 | Exercise or conversion of derivative security |
| 2026-06-30 | CTNM | Sell | 2.5K | $0 | Exercise or conversion of derivative security |
| 2026-06-30 | CTNM | Buy | 2.5K | $3K | Exercise or conversion of derivative security |
| 2026-06-30 | CTNM | Buy | 7.5K | $8K | Exercise or conversion of derivative security |
| 2026-06-30 | CTNM | Sell | 10.0K | $160K | Open market or private sale |
| 2026-06-10 | KPRX | Buy | 25.0K | $0 | Grant, award or other acquisition |
Activity shown covers the trailing 90 days of SEC Form 4 filings. "Buy" and "sell" follow the SEC acquired/disposed codes and include compensation events (grants, option exercises, tax withholding) unless noted. Historical fact, not investment advice.
Follow Stengone's next move
Real-time Form 4 alerts, insider track records, and cluster detection — matched to your watchlist.